BillionToOne
BLLN
95.75
-4.19
-4.19%
BillionToOne
US · BLLN
#2109 by market cap
Listed 2025
95.75
-4.19
-4.19%
Live - 5344 symbols - heartbeat 100s ago
· 2026-10-08 08:12
Pre-market
95.75
0.00%
After-hours
95.75
0.00%
- Market cap
- 4.52B
- P/E (TTM)i
- 135.05
- P/Bi
- 8.42
- EPSi
- 0.06
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on BLLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 6.2 percentage points.
Institutional ownership
- Held by institutions
- 64.25% -6.17pp
- Institutions
- 185 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund30.63%
Mutual Fund25.55%
Individual/Insider10.56%
Private Company4.65%
Hedge Fund2.26%
Public Company0.54%
Government Pension Fund0.43%
Family Office/Trust0.10%
Other25.19%
Top holders as of 2025-11-07
Hummingbird Ventures Management NV
16.71% · 7.89M sh
Libertus Capital Limited
7.55% · 3.56M sh
Oguzhan Atay
4.98% · 2.35M sh
David Tsao
4.89% · 2.31M sh
Wipro Enterprises Private Limited
3.78% · 1.78M sh
Adams Street Partners, LLC
3.63% · 1.71M sh
NeoTribe Ventures
2.45% · 1.15M sh
T. Rowe Price Group, Inc.
2.34% · 1.10M sh
Baillie Gifford
1.91% · 901.42K sh
Vanguard Capital Management, LLC
1.79% · 842.34K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 7 buys · 43 sells
| Name | Role | Stake |
|---|---|---|
| Hummingbird Ventures Management NV | -- | 16.71% |
| Oguzhan Atay | Chairperson & CEO | 4.98% |
| David Tsao | Co-Founder, President, CTO & Director | 4.89% |
| Shan Sakakibara | Chief Product Officer | 0.42% |
| Krishna Kolluri | Independent Director | 0.07% |
| Firat Ileri | Lead Independent Director | 0.06% |
| John Bosch | Senior Vice President of Laboratory Operations | 0.05% |
| Nancy Johnson | Senior Vice President of Sales & Commercial Operations | 0.01% |
| Akshay Rai | Independent Director | 0.01% |
| Thomas Lynch | Chief Compliance Officer, General Counsel & Secretary | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | David Tsao | Co-Founder, President, CTO & Director | Intent to Sell (Form 144) | -20,000 | $108.15 |
| 2026-10-04 | David Tsao | Co-Founder, President, CTO & Director | Intent to Sell (Form 144) | -1,750 | $105.15 |
| 2026-10-04 | John Bosch | Senior Vice President of Laboratory Operations | Intent to Sell (Form 144) | -2,834 | $105.15 |
| 2026-09-27 | Oguzhan Atay | Chairperson & CEO | Automatic Disposition | -2,666 | $120.64 |
| 2026-09-27 | Oguzhan Atay | Chairperson & CEO | Derivative Exercise and Sale | -8,333 | $2.80–120.64 |
| 2026-09-23 | David Tsao | Co-Founder, President, CTO & Director | Derivative Exercise and Sale | -3,333 | $2.80–125.00 |
| 2026-09-23 | John Bosch | Senior Vice President of Laboratory Operations | Automatic Disposition | -1,416 | $120.00 |
| 2026-09-20 | John Bosch | Senior Vice President of Laboratory Operations | Automatic Disposition | -1,416 | $106.61 |
| 2026-09-16 | Thomas Lynch | Chief Compliance Officer, General Counsel & Secretary | Derivative Exercise and Sale | -35,112 | $8.65–110.36 |
| 2026-09-13 | Oguzhan Atay | Chairperson & CEO | Automatic Disposition | -5,332 | $98.00 |
| 2026-09-13 | Oguzhan Atay | Chairperson & CEO | Derivative Exercise and Sale | -24,999 | $2.80–101.49 |
| 2026-09-09 | Shan Sakakibara | Chief Product Officer | Other Disposition | -3,500 | -- |
| 2026-09-08 | Oguzhan Atay | Chairperson & CEO | Derivative Exercise and Sale | -20,000 | -- |
| 2026-09-08 | David Tsao | Co-Founder, President, CTO & Director | Derivative Exercise and Sale | -20,000 | $2.80–100.00 |
| 2026-09-08 | John Bosch | Senior Vice President of Laboratory Operations | Automatic Disposition | -1,416 | $97.54 |
| 2026-09-07 | Thomas Lynch | Chief Compliance Officer, General Counsel & Secretary | Derivative Exercise and Sale | -20,000 | $8.65–101.41 |
| 2026-09-07 | David Tsao | Co-Founder, President, CTO & Director | Derivative Exercise and Sale | -20,000 | -- |
| 2026-08-25 | NeoTribe Ventures | -- | Other Acquisition | +48,491 | -- |
| 2026-08-25 | NeoTribe Ventures | -- | Other Disposition | -484,442 | -- |
| 2026-08-24 | David Tsao | Co-Founder, President, CTO & Director | Derivative Exercise and Sale | -10,000 | $2.80–100.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:12:47 · For reference only, not investment advice and not tailored to your situation.